Format

Send to

Choose Destination
J Menopausal Med. 2016 Apr;22(1):9-13. doi: 10.6118/jmm.2016.22.1.9. Epub 2016 Apr 26.

Flibanserin for Treating Hypoactive Sexual Desire Disorder.

Author information

1
Department of Obstetrics and Gynecology, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Korea.
2
Department of Obstetrics and Gynecology, Soonchunhyang University College of Medicine, Bucheon, Korea.
3
Department of Obstetrics and Gynecology, School of Medicine, Chosun University, Gwangju, Korea.

Abstract

There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon. Authors wrote this article to acknowledge flibanserin to sexologists for females or physicians for menopausal medicine, so that this agent can be safely used for females who have HSDD.

KEYWORDS:

Flibanserin; Sexual behavior; Sexual dysfunctions, psychological; Sildenafil citrate

Supplemental Content

Full text links

Icon for Korean Society of Menopause Icon for PubMed Central
Loading ...
Support Center